



Dominican Republic
Country Operational Plan
FY 2017



Budget Summary Reports

Summary of Planned Funding by Agency and Funding Source

Agency	Funding Source			Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
	GAP	GHP-State	GHP-USAID			
USAID		856,068	3,068,932	3,925,000	3,875,000	7,800,000
DOD		0		0	211,000	211,000
HHS/CDC	387,500	3,437,500		3,825,000	3,664,000	7,489,000
Total	387,500	4,293,568	3,068,932	7,750,000	7,750,000	15,500,000

Summary of Planned Funding by Budget Code and Agency

Budget Code	Agency			On Hold Amount	Total
	DOD	HHS/CDC	USAID		
HBHC		121,439	442,983	0	564,422
HLAB		232,091		0	232,091
HTXS	0	986,369	1,562,552	0	2,548,921
HVCT		426,591	422,537	0	849,128
HVMS	0	1,182,343	424,697	0	1,607,040
HVOP		272,175	445,206	0	717,381
HVSI	0	187,195	28,126	0	215,321
HVTB		55,285		0	55,285
OHSS	0	361,512	598,899	0	960,411
	0	3,825,000	3,925,000	0	7,750,000



Technical Areas

Technical Area Summary

Technical Area: Care

Budget Code	Budget Code Planned Amount	On Hold Amount
HBHC	497,862	0
HVTB	28,018	0
Total Technical Area Planned Funding:	525,880	0

Technical Area: Governance and Systems

Budget Code	Budget Code Planned Amount	On Hold Amount
HLAB	100,000	0
HVSI	44,827	0
OHSS	786,941	0
Total Technical Area Planned Funding:	931,768	0

Technical Area: Prevention

Budget Code	Budget Code Planned Amount	On Hold Amount
HVCT	680,743	0
HVOP	521,911	0
Total Technical Area Planned Funding:	1,202,654	0

Technical Area: Treatment

Budget Code	Budget Code Planned Amount	On Hold Amount
HTXS	2,039,716	0
Total Technical Area Planned Funding:	2,039,716	0





Technical Area Summary Indicators and Targets

Indicator Number	Label	2018
PrEP_NEW_DSD	PrEP_NEW_DSD Number of individuals who have received antiretroviral pre-exposure prophylaxis (PrEP) to prevent HIV infection in the reporting period.	n/a
	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	150
	Male 10-14	
	Male 15-19	3
	Male 20-24	21
	Male 25-49	111
	Male 50+	15
	Female 10-14	
	Female 15-19	
	Female 20-24	
	Female 25-49	
	Female 50+	
	(15-19)	
	(20-24)	
	FSW	
	MSM	150
TG		
PP_PREV_DSD	PP_PREV_DSD Percentage of the target population who completed a standardized HIV prevention intervention including the minimum	n/a

	components during the reporting period (DSD)	
	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	44,513
	Total number of people in the target population	
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	3,491
	Age/sex: 20-24 Male	6,429
	Age/sex: 25-49 Male	12,546
	Age/sex: 50+ Male	1,726
	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	3,303
	Age/sex: 20-24 Female	6,104
	Age/sex: 25-49 Female	9,963
	Age/sex: 50+ Female	950
	Aggregated Age/sex: <15 Male	
	Aggregated Age/sex: 15+ Male	
	Aggregated Age/sex: <15 Female	
	Aggregated Age/sex: 15+ Female	
KP_PREV_DSD	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD)	n/a
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards	12,887

	required	
	Total estimated number of key population in the catchment area	
	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	12,290
	By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Female	597

	sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: People in	

	prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Men who have sex with men who are sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Transgender who are sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Males who inject drugs (Male PWID) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Men who have sex with men/Transgender	

	(MSM/TG) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Denominator: Total estimated number of key population in the catchment area)	
	By Service: KP known status	
	By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program	
	By New Client Status: New beneficiary	
	By New Client Status: Returning beneficiary within the current report period	
TB_STAT_DSD	TB_STAT_DSD Percentage of registered new and relapsed TB cases with documented HIV status.	80 %
	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	141
	Total number of registered new and relapsed TB cases, during the reporting period.	177
	Age/Sex: <1 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: 1-9 (Numerator: Number	

	of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 20-24 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 15-19 (Numerator: Number of registered new and relapsed TB cases with	

	documented HIV status, during the reporting period)	
	Age/Sex: Female 20-24 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	70
	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	71

	reporting period)	
	Result: Known HIV positive at service entry	
	Result: New HIV positive	
	Result: HIV Negative	
	Age/Sex: <1 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: 1-9 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 50+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 10-14 (Denominator: Total number of	

	registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 50+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	88
	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	89
HTC_TST_DSD	Number of individuals who received	90,116



	T&C services for HIV and received their test results during the past 12 months	
	By Test Result: Positive	4,233
	Service Delivery Point (Community) Homebased testing: 10-14, Female, Negative	
	Service Delivery Point (Community) Homebased testing: 10-14, Female, Positive	
	Service Delivery Point (Community) Homebased testing: 10-14, Male, Negative	
	Service Delivery Point (Community) Homebased testing: 10-14, Male, Positive	
	Service Delivery Point (Community) Homebased testing: 15-19, Female, Negative	
	Service Delivery Point (Community) Homebased testing: 15-19, Female, Positive	
	Service Delivery Point (Community) Homebased testing: 15-19, Male, Negative	
	Service Delivery Point (Community) Homebased testing: 15-19, Male, Positive	
	Service Delivery Point (Community) Homebased testing: 20-24, Female, Negative	
	Service Delivery Point (Community) Homebased testing: 20-24, Female, Positive	
	Service Delivery Point (Community)	

	Homebased testing: 20-24, Male, Negative	
	Service Delivery Point (Community) Homebased testing: 20-24, Male, Positive	
	Service Delivery Point (Community) Homebased testing: 25-49, Female, Negative	
	Service Delivery Point (Community) Homebased testing: 25-49, Female, Positive	
	Service Delivery Point (Community) Homebased testing: 25-49, Male, Negative	
	Service Delivery Point (Community) Homebased testing: 25-49, Male, Positive	
	Service Delivery Point (Community) Homebased testing: 50+, Female, Negative	
	Service Delivery Point (Community) Homebased testing: 50+, Female, Positive	
	Service Delivery Point (Community) Homebased testing: 50+, Male, Negative	
	Service Delivery Point (Community) Homebased testing: 50+, Male, Positive	
	Service Delivery Point (Community) Homebased testing: Unknown Age, Female, Negative	
	Service Delivery Point (Community) Homebased testing: Unknown Age, Female, Positive	

	Service Delivery Point (Community) Homebased testing: Unknown Age, Male, Negative	
	Service Delivery Point (Community) Homebased testing: Unknown Age, Male, Positive	
	Service Delivery Point (Community) Homebased testing: <1, Negative	
	Service Delivery Point (Community) Homebased testing: <1, Positive	
	Service Delivery Point (Community) Homebased testing: 1-9, Negative	
	Service Delivery Point (Community) Homebased testing: 1-9, Positive	
	Service Delivery Point by Agg Age (Community) Homebased testing: <15, Female, Negative	
	Service Delivery Point by Agg Age (Community) Homebased testing: <15, Female, Positive	
	Service Delivery Point by Agg Age (Community) Homebased testing: <15, Male, Negative	
	Service Delivery Point by Agg Age (Community) Homebased testing: <15, Male, Positive	
	Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Negative	
	Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Positive	
	Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Male, Negative	

	Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Male, Positive	
	Service Delivery Point by Agg Age (Community) Homebased testing: Unknown Age, Female, Negative	
	Service Delivery Point by Agg Age (Community) Homebased testing: Unknown Age, Female, Positive	
	Service Delivery Point by Agg Age (Community) Homebased testing: Unknown Age, Male, Negative	
	Service Delivery Point by Agg Age (Community) by Aggregated Age: Homebased testing: Unknown Age, Male, Positive	
	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	
	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	
	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	
	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	
	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	
	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	
	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	
	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	
	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	

	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	
	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	
	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	
	Service Delivery Point (Facility) Inpatient: 25-49, Female, Negative	
	Service Delivery Point (Facility) Inpatient: 25-49, Female, Positive	
	Service Delivery Point (Facility) Inpatient: 25-49, Male, Negative	
	Service Delivery Point (Facility) Inpatient: 25-49, Male, Positive	
	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	
	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	
	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	
	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	
	Service Delivery Point (Facility) Inpatient: Unknown Age, Female, Negative	
	Service Delivery Point (Facility) Inpatient: Unknown Age, Female, Positive	
	Service Delivery Point (Facility) Inpatient: Unknown Age, Male, Negative	
	Service Delivery Point (Facility) Inpatient: Unknown Age, Male, Positive	

	Service Delivery Point (Facility) Inpatient: <1, Negative	
	Service Delivery Point (Facility) Inpatient: <1, Positive	
	Service Delivery Point (Facility) Inpatient: 1-9, Negative	
	Service Delivery Point (Facility) Inpatient: 1-9, Positive	
	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Female, Negative	
	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Female, Positive	
	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Male, Negative	
	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Male, Positive	
	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Female, Negative	808
	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Female, Positive	90
	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Male, Negative	911
	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Male, Positive	101
	Service Delivery Point by Agg Age (Facility) Inpatient: Unknown Age, Female, Negative	

	Service Delivery Point by Agg Age (Facility) Inpatient: Unknown Age, Female, Positive	
	Service Delivery Point by Agg Age (Facility) Inpatient: Unknown Age, Male, Negative	
	Service Delivery Point by Agg Age (Facility) Inpatient: Unknown Age, Male, Positive	
	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Negative	
	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Positive	
	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Negative	
	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Positive	
	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	
	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	
	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	
	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	
	Service Delivery Point (Community) Mobile Testing: 20-24, Female,	

	Negative	
	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	
	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	
	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	
	Service Delivery Point (Community) Mobile Testing: 25-49, Female, Negative	
	Service Delivery Point (Community) Mobile Testing: 25-49, Female, Positive	
	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Negative	
	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Positive	
	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	
	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	
	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	
	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	
	Service Delivery Point (Community) Mobile Testing: Unknown Age,	

	Female, Negative	
	Service Delivery Point (Community) Mobile Testing: Unknown Age, Female, Positive	
	Service Delivery Point (Community) Mobile Testing: Unknown Age, Male, Negative	
	Service Delivery Point (Community) Mobile Testing: Unknown Age, Male, Positive	
	Service Delivery Point (Community) Mobile Testing: <1, Negative	
	Service Delivery Point (Community) Mobile Testing: <1, Positive	
	Service Delivery Point (Community) Mobile Testing: 1-9, Negative	
	Service Delivery Point (Community) Mobile Testing: 1-9, Positive	
	Service Delivery Point by Agg Age(Community) Mobile Testing: <15, Female, Negative	
	Service Delivery Point by Agg Age(Community) Mobile Testing: <15, Female, Positive	
	Service Delivery Point by Agg Age(Community) Mobile Testing: <15, Male, Negative	
	Service Delivery Point by Agg Age(Community) Mobile Testing: <15, Male, Positive	
	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Female, Negative	8,743
	Service Delivery Point by Agg Age(Community) Mobile Testing:	270

	15+, Female, Positive	
	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Male, Negative	20,401
	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Male, Positive	631
	Service Delivery Point by Agg Age(Community) Mobile Testing: Unknown Age, Female, Negative	
	Service Delivery Point by Agg Age(Community) Mobile Testing: Unknown Age, Female, Positive	
	Service Delivery Point by Agg Age(Community) Mobile Testing: Unknown Age, Male, Negative	
	Service Delivery Point by Agg Age(Community) Mobile Testing: Unknown Age, Male, Positive	
	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	
	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	
	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	
	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	
	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	
	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	

	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	
	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	
	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	
	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	
	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	
	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	
	Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative	
	Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive	
	Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	
	Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	
	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	
	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	
	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	
	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	
	Service Delivery Point (Facility) Other PITC: Unknown Age,	

	Female, Negative	
	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Positive	
	Service Delivery Point (Facility) Other PITC: Unknown Age, Male, Negative	
	Service Delivery Point (Facility) Other PITC: Unknown Age, Male, Positive	
	Service Delivery Point (Facility) Other PITC: <1, Negative	
	Service Delivery Point (Facility) Other PITC: <1, Positive	
	Service Delivery Point (Facility) Other PITC: 1-9, Negative	
	Service Delivery Point (Facility) Other PITC: 1-9, Positive	
	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Negative	
	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Positive	
	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Negative	
	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Positive	
	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Negative	22,095
	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female,	1,170

	Positive	
	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Negative	18,621
	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Positive	1,013
	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Negative	
	Service Delivery Point by Agg Age (Facility) Other PITC: Unknown Age, Female, Positive	
	Service Delivery Point by Agg Age (Facility) Other PITC: Unknown Age, Male, Negative	
	Service Delivery Point by Agg Age (Facility) Other PITC: Unknown Age, Male, Positive	
	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	
	Service Delivery Point (Community) Other: 10-14, Female, Positive	
	Service Delivery Point (Community) Other: 10-14, Male, Negative	
	Service Delivery Point (Community) Other: 10-14, Male, Positive	
	Service Delivery Point (Community) Other: 15-19, Female, Negative	
	Service Delivery Point (Community) Other: 15-19, Female, Positive	
	Service Delivery Point (Community) Other: 15-19, Male, Negative	

	Service Delivery Point (Community) Other: 15-19, Male, Positive	
	Service Delivery Point (Community) Other: 20-24, Female, Negative	
	Service Delivery Point (Community) Other: 20-24, Female, Positive	
	Service Delivery Point (Community) Other: 20-24, Male, Negative	
	Service Delivery Point (Community) Other: 20-24, Male, Positive	
	Service Delivery Point (Community) Other: 25-49, Female, Negative	
	Service Delivery Point (Community) Other: 25-49, Female, Positive	
	Service Delivery Point (Community) Other: 25-49, Male, Negative	
	Service Delivery Point (Community) Other: 25-49, Male, Positive	
	Service Delivery Point (Community) Other: 50+, Female, Negative	
	Service Delivery Point (Community) Other: 50+, Female, Positive	
	Service Delivery Point (Community) Other: 50+, Male, Negative	
	Service Delivery Point (Community) Other: 50+, Male, Positive	
	Service Delivery Point (Community) Other: Unknown Age, Female, Negative	
	Service Delivery Point (Community) Other: Unknown Age, Female, Positive	
	Service Delivery Point (Community) Other: Unknown Age, Male,	

	Negative	
	Service Delivery Point (Community) Other: Unknown Age, Male, Positive	
	Service Delivery Point (Community) Other: <1, Negative	
	Service Delivery Point (Community) Other: <1, Positive	
	Service Delivery Point (Community) Other: 1-9, Negative	
	Service Delivery Point (Community) Other: 1-9, Positive	
	Service Delivery Point by Agg Age (Community) Other: <15, Female, Negative	
	Service Delivery Point by Agg Age (Community) Other: <15, Female, Positive	
	Service Delivery Point by Agg Age (Community) Other: <15, Male, Negative	
	Service Delivery Point by Agg Age (Community) Other: <15, Male, Positive	
	Service Delivery Point by Agg Age (Community) Other: 15+, Female, Negative	1,501
	Service Delivery Point by Agg Age (Community) Other: 15+, Female, Positive	79
	Service Delivery Point by Agg Age (Community) Other: 15+, Male, Negative	9,517
	Service Delivery Point by Agg Age (Community) Other: 15+, Male, Positive	501

	Positive	
	Service Delivery Point by Agg Age (Community) Other: Unknown Age, Female, Negative	
	Service Delivery Point by Agg Age (Community) Other: Unknown Age, Female, Positive	
	Service Delivery Point by Agg Age (Community) Other: Unknown Age, Male, Negative	
	Service Delivery Point by Agg Age (Community) Other: Unknown Age, Male, Positive	
	Service Delivery Point (Facility) Pediatric : <5 Negative	
	Service Delivery Point (Facility) Pediatric : <5 Positive	
	Service Delivery Point (Facility) TB: 10-14, Female, Negative	
	Service Delivery Point (Facility) TB: 10-14, Female, Positive	
	Service Delivery Point (Facility) TB: 10-14, Male, Negative	
	Service Delivery Point (Facility) TB: 10-14, Male, Positive	
	Service Delivery Point (Facility) TB: 15-19, Female, Negative	
	Service Delivery Point (Facility) TB: 15-19, Female, Positive	
	Service Delivery Point (Facility) TB: 15-19, Male, Negative	
	Service Delivery Point (Facility) TB: 15-19, Male, Positive	
	Service Delivery Point (Facility) TB:	

	20-24, Female, Negative	
	Service Delivery Point (Facility) TB: 20-24, Female, Positive	
	Service Delivery Point (Facility) TB: 20-24, Male, Negative	
	Service Delivery Point (Facility) TB: 20-24, Male, Positive	
	Service Delivery Point (Facility) TB: 25-49, Female, Negative	
	Service Delivery Point (Facility) TB: 25-49, Female, Positive	
	Service Delivery Point (Facility) TB: 25-49, Male, Negative	
	Service Delivery Point (Facility) TB: 25-49, Male, Positive	
	Service Delivery Point (Facility) TB: 50+, Female, Negative	
	Service Delivery Point (Facility) TB: 50+, Female, Positive	
	Service Delivery Point (Facility) TB: 50+, Male, Negative	
	Service Delivery Point (Facility) TB: 50+, Male, Positive	
	Service Delivery Point (Facility) TB: Unknown Age, Female, Negative	
	Service Delivery Point (Facility) TB: Unknown Age, Female, Positive	
	Service Delivery Point (Facility) TB: Unknown Age, Male, Negative	
	Service Delivery Point (Facility) TB: Unknown Age, Male, Positive	
	Service Delivery Point (Facility) TB: <1, Negative	
	Service Delivery Point (Facility) TB:	

	<1, Positive	
	Service Delivery Point (Facility) TB: 1-9, Negative	
	Service Delivery Point (Facility) TB: 1-9, Positive	
	Service Delivery Point by Agg Age (Facility) TB: <15, Female, Negative	
	Service Delivery Point by Agg Age (Facility) TB: <15, Female, Positive	
	Service Delivery Point by Agg Age (Facility) TB: <15, Male, Negative	
	Service Delivery Point by Agg Age (Facility) TB: <15, Male, Positive	
	Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Negative	
	Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Positive	
	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Negative	
	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Positive	
	Service Delivery Point by Agg Age (Facility) TB: Unknown Age, Female, Negative	
	Service Delivery Point by Agg Age (Facility) TB: Unknown Age, Female, Positive	
	Service Delivery Point by Agg Age (Facility) TB: Unknown Age, Male, Negative	
	Service Delivery Point by Agg Age (Facility) TB: Unknown Age, Male,	

	Positive	
	Service Delivery Point (Facility) VMMC: <1, Negative	
	Service Delivery Point (Facility) VMMC: <1, Positive	
	Service Delivery Point (Facility) VMMC: 10-14, Negative	
	Service Delivery Point (Facility) VMMC: 10-14, Positive	
	Service Delivery Point (Facility) VMMC: 15-19, Negative	
	Service Delivery Point (Facility) VMMC: 15-19, Positive	
	Service Delivery Point (Facility) VMMC: 1-9, Negative	
	Service Delivery Point (Facility) VMMC: 1-9, Positive	
	Service Delivery Point (Facility) VMMC: 20-24, Negative	
	Service Delivery Point (Facility) VMMC: 20-24, Positive	
	Service Delivery Point (Facility) VMMC: 25-49, Negative	
	Service Delivery Point (Facility) VMMC: 25-49, Positive	
	Service Delivery Point (Facility) VMMC: 50+, Negative	
	Service Delivery Point (Facility) VMMC: 50+, Positive	
	Service Delivery Point (Facility) VMMC: Unknown Age, Negative	
	Service Delivery Point (Facility) VMMC: Unknown Age, Positive	
	Service Delivery Point (Facility)	

	VMMC: <15, Negative	
	Service Delivery Point by Agg Age (Facility) VMMC: <15, Positive	
	Service Delivery Point by Agg Age (Facility) VMMC: 15+, Negative	
	Service Delivery Point by Agg Age (Facility) VMMC: 15+, Positive	
	Service Delivery Point by Agg Age (Facility) VMMC: Unknown Age, Negative	
	Service Delivery Point by Agg Age (Facility) VMMC: Unknown Age, Positive	
	Service Delivery Point (Facility) Index: 10-14, Female, Negative	
	Service Delivery Point (Facility) Index: 10-14, Female, Positive	
	Service Delivery Point (Facility) Index: 10-14, Male, Negative	
	Service Delivery Point (Facility) Index: 10-14, Male, Positive	
	Service Delivery Point (Facility) Index: 15-19, Female, Negative	
	Service Delivery Point (Facility) Index: 15-19, Female, Positive	
	Service Delivery Point (Facility) Index: 15-19, Male, Negative	
	Service Delivery Point (Facility) Index: 15-19, Male, Positive	
	Service Delivery Point (Facility) Index: 20-24, Female, Negative	
	Service Delivery Point (Facility) Index: 20-24, Female, Positive	
	Service Delivery Point (Facility)	

	Index: 20-24, Male, Negative	
	Service Delivery Point (Facility)	
	Index: 20-24, Male, Positive	
	Service Delivery Point (Facility)	
	Index: 25-49, Female, Negative	
	Service Delivery Point (Facility)	
	Index: 25-49, Female, Positive	
	Service Delivery Point (Facility)	
	Index: 25-49, Male, Negative	
	Service Delivery Point (Facility)	
	Index: 25-49, Male, Positive	
	Service Delivery Point (Facility)	
	Index: 50+, Female, Negative	
	Service Delivery Point (Facility)	
	Index: 50+, Female, Positive	
	Service Delivery Point (Facility)	
	Index: 50+, Male, Negative	
	Service Delivery Point (Facility)	
	Index: 50+, Male, Positive	
	Service Delivery Point (Facility)	
	Index: Unknown Age, Female, Negative	
	Service Delivery Point (Facility)	
	Index: Unknown Age, Female, Positive	
	Service Delivery Point (Facility)	
	Index: Unknown Age, Male, Negative	
	Service Delivery Point (Facility)	
	Index: Unknown Age, Male, Positive	
	Service Delivery Point (Facility)	
	Index: <1, Negative	
	Service Delivery Point (Facility)	

	Index: <1, Positive	
	Service Delivery Point (Facility) Index: 1-9, Negative	
	Service Delivery Point (Facility) Index: 1-9, Positive	
	Service Delivery Point Agg Age (Facility) Index: <15, Female, Negative	
	Service Delivery Point Agg Age (Facility) Index: <15, Female, Positive	
	Service Delivery Point Agg Age (Facility) Index: <15, Male, Negative	
	Service Delivery Point Agg Age (Facility) Index: <15, Male, Positive	
	Service Delivery Point Agg Age (Facility) Index: 15+, Female, Negative	1,028
	Service Delivery Point Agg Age (Facility) Index: 15+, Female, Positive	183
	Service Delivery Point Agg Age (Facility) Index: 15+, Male, Negative	871
	Service Delivery Point Agg Age (Facility) Index: 15+, Male, Positive	154
	Service Delivery Point Agg Age (Facility) Index: Unknown Age, Female, Negative	
	Service Delivery Point Agg Age (Facility) Index: Unknown Age, Female, Positive	
	Service Delivery Point Agg Age (Facility) Index: Unknown Age,	

	Male, Negative	
	Service Delivery Point Agg Age (Facility) Index: Unknown Age, Male, Positive	
	By Key Population: FSW, Negative	5,046
	By Key Population: FSW, Positive	294
	By Key Population: MSM, Negative	17,434
	By Key Population: MSM, Positive	976
	By Key Population: People in prisons and other enclosed settings, Negative	
	By Key Population: People in prisons and other enclosed settings, Positive	
	By Key Population: PWID, Negative	
	By Key Population: PWID, Positive	
	By Key Population: TG, Negative	
	By Key Population: TG, Positive	
	Service Delivery Point (Facility) Malnutrition: Negative	
	Service Delivery Point (Facility) Malnutrition: Positive	
	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	
	Service Delivery Point (Community) Index Mod: 10-14, Female, Positive	
	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	
	Service Delivery Point (Community) Index Mod: 10-14, Male, Positive	
	Service Delivery Point (Community) Index Mod: 15-19, Female,	

	Negative	
	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	
	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	
	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	
	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	
	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	
	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	
	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	
	Service Delivery Point (Community) Index Mod: 25-49, Female, Negative	
	Service Delivery Point (Community) Index Mod: 25-49, Female, Positive	
	Service Delivery Point (Community) Index Mod: 25-49, Male, Negative	
	Service Delivery Point (Community) Index Mod: 25-49, Male, Positive	
	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	
	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	
	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	
	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	
	Service Delivery Point (Community)	

	Index Mod: Unknown Age, Female, Negative	
	Service Delivery Point (Community) Index Mod: Unknown Age, Female, Positive	
	Service Delivery Point (Community) Index Mod: Unknown Age, Male, Negative	
	Service Delivery Point (Community) Index Mod: Unknown Age, Male, Positive	
	Service Delivery Point (Community) Index Mod: <1, Negative	
	Service Delivery Point (Community) Index Mod: <1, Positive	
	Service Delivery Point (Community) Index Mod: 1-9, Negative	
	Service Delivery Point (Community) Index Mod: 1-9, Positive	
	Service Delivery Point by Agg Age (Community) Index Mod: <15, Female, Negative	
	Service Delivery Point by Agg Age (Community) Index Mod: <15, Female, Positive	
	Service Delivery Point by Agg Age (Community) Index Mod: <15, Male, Negative	
	Service Delivery Point by Agg Age (Community) Index Mod: <15, Male, Positive	
	Service Delivery Point by Agg Age (Community) Index Mod: 15+, Female, Negative	1,301
	Service Delivery Point by Agg Age	77

	(Community) Index Mod: 15+, Female, Positive	
	Service Delivery Point by Agg Age (Community) Index Mod: 15+, Male, Negative	1,804
	Service Delivery Point by Agg Age (Community) Index Mod: 15+, Male, Positive	164
	Service Delivery Point by Agg Age (Community) Index Mod: Unknown Age, Female, Negative	
	Service Delivery Point by Agg Age (Community) Index Mod: Unknown Age, Female, Positive	
	Service Delivery Point by Agg Age (Community) Index Mod: Unknown Age, Male, Negative	
	Service Delivery Point by Agg Age (Community) Index Mod: Unknown Age, Male, Positive	
	Service Delivery Point (Facility) ANC: <1, Negative	
	Service Delivery Point (Facility) ANC: <1, Positive	
	Service Delivery Point (Facility) ANC: 10-14, Negative	
	Service Delivery Point (Facility) ANC: 10-14, Positive	
	Service Delivery Point (Facility) ANC: 15-19, Negative	
	Service Delivery Point (Facility) ANC: 15-19, Positive	
	Service Delivery Point (Facility) ANC: 1-9, Negative	

	Service Delivery Point (Facility) ANC: 1-9, Positive	
	Service Delivery Point (Facility) ANC: 20-24, Negative	
	Service Delivery Point (Facility) ANC: 20-24, Positive	
	Service Delivery Point (Facility) ANC: 25-49, Negative	
	Service Delivery Point (Facility) ANC: 25-49, Positive	
	Service Delivery Point (Facility) ANC: 50+, Negative	
	Service Delivery Point (Facility) ANC: 50+, Positive	
	Service Delivery Point (Facility) ANC: Unknown Age, Negative	
	Service Delivery Point (Facility) ANC: Unknown Age, Positive	
	Service Delivery Point by Agg Age (Facility) ANC: <15, Negative	
	Service Delivery Point by Agg Age (Facility) ANC: <15, Positive	
	Service Delivery Point by Agg Age (Facility) ANC: 15+, Negative	
	Service Delivery Point by Agg Age (Facility) ANC: 15+, Positive	
	Service Delivery Point by Agg Age (Facility) ANC: Unknown Age, Negative	
	Service Delivery Point by Agg Age (Facility) ANC: Unknown Age, Positive	
	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	

	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	
	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	
	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	
	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	
	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	
	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	
	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	
	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	
	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	
	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	
	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	
	Service Delivery Point (Facility) VCT: 25-49, Female, Negative	
	Service Delivery Point (Facility) VCT: 25-49, Female, Positive	
	Service Delivery Point (Facility) VCT: 25-49, Male, Negative	
	Service Delivery Point (Facility) VCT: 25-49, Male, Positive	
	Service Delivery Point (Facility) VCT: 50+, Female, Negative	
	Service Delivery Point (Facility) VCT: 50+, Female, Positive	

	Service Delivery Point (Facility) VCT: 50+, Male, Negative	
	Service Delivery Point (Facility) VCT: 50+, Male, Positive	
	Service Delivery Point (Facility) VCT: Unknown Age, Female, Negative	
	Service Delivery Point (Facility) VCT: Unknown Age, Female, Positive	
	Service Delivery Point (Facility) VCT:	
	Service Delivery Point (Facility) VCT: Unknown Age, Male, Positive	
	Service Delivery Point (Facility) VCT: <1, Negative	
	Service Delivery Point (Facility) VCT: <1, Positive	
	Service Delivery Point (Facility) VCT: 1-9, Negative	
	Service Delivery Point (Facility) VCT: 1-9, Positive	
	Service Delivery Point by Agg Age (Facility) VCT: <15, Female, Negative	
	Service Delivery Point by Agg Age (Facility) VCT: <15, Female, Positive	
	Service Delivery Point by Agg Age (Facility) VCT: <15, Male, Negative	
	Service Delivery Point by Agg Age (Facility) VCT: <15, Male, Positive	
	Service Delivery Point by Agg Age (Facility) VCT: 15+, Female,	576

	Negative	
	Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Positive	30
	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Negative	576
	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Positive	30
	Service Delivery Point by Agg Age (Facility) VCT: Unknown Age, Female, Negative	
	Service Delivery Point by Agg Age (Facility) VCT: Unknown Age, Female, Positive	
	Service Delivery Point by Agg Age (Facility) VCT: Unknown Age, Male, Negative	
	Service Delivery Point by Agg Age (Facility) VCT: Unknown Age, Male, Positive	
	Service Delivery Point (Community) VCT Mod: 10-14, Female, Negative	
	Service Delivery Point (Community) VCT Mod: 10-14, Female, Positive	
	Service Delivery Point (Community) VCT Mod: 10-14, Male, Negative	
	Service Delivery Point (Community) VCT Mod: 10-14, Male, Positive	
	Service Delivery Point (Community) VCT Mod: 15-19, Female, Negative	
	Service Delivery Point (Community) VCT Mod: 15-19, Female, Positive	
	Service Delivery Point (Community) VCT Mod: 15-19, Male, Negative	

	Service Delivery Point (Community) VCT Mod: 15-19, Male, Positive	
	Service Delivery Point (Community) VCT Mod: 20-24, Female, Negative	
	Service Delivery Point (Community) VCT Mod: 20-24, Female, Positive	
	Service Delivery Point (Community) VCT Mod: 20-24, Male, Negative	
	Service Delivery Point (Community) VCT Mod: 20-24, Male, Positive	
	Service Delivery Point (Community) VCT Mod: 25-49, Female, Negative	
	Service Delivery Point (Community) VCT Mod: 25-49, Female, Positive	
	Service Delivery Point (Community) VCT Mod: 25-49, Male, Negative	
	Service Delivery Point (Community) VCT Mod: 25-49, Male, Positive	
	Service Delivery Point (Community) VCT Mod: 50+, Female, Negative	
	Service Delivery Point (Community) VCT Mod: 50+, Female, Positive	
	Service Delivery Point (Community) VCT Mod: 50+, Male, Negative	
	Service Delivery Point (Community) VCT Mod: 50+, Male, Positive	
	Service Delivery Point (Community) VCT Mod: Unknown Age, Female, Negative	
	Service Delivery Point (Community) VCT Mod: Unknown Age, Female, Positive	
	Service Delivery Point (Community) VCT Mod: Unknown Age, Male,	

	Negative	
	Service Delivery Point (Community) VCT Mod: Unknown Age, Male, Positive	
	Service Delivery Point (Community) VCT Mod: <1, Negative	
	Service Delivery Point (Community) VCT Mod: <1, Positive	
	Service Delivery Point (Community) VCT Mod: 1-9, Negative	
	Service Delivery Point (Community) VCT Mod: 1-9, Positive	
	Service Delivery Point by Agg Age (Community) VCT Mod: <15, Female, Negative	
	Service Delivery Point by Agg Age (Community) VCT Mod: <15, Female, Positive	
	Service Delivery Point by Agg Age (Community) VCT Mod: <15, Male, Negative	
	Service Delivery Point by Agg Age (Community) VCT Mod: <15, Male, Positive	
	Service Delivery Point by Agg Age (Community) VCT Mod: 15+, Female, Negative	
	Service Delivery Point by Agg Age (Community) VCT Mod: 15+, Female, Positive	
	Service Delivery Point by Agg Age (Community) VCT Mod: 15+, Male, Negative	
	Service Delivery Point by Agg Age (Community) VCT Mod: 15+, Male,	

	Positive	
	Service Delivery Point by Agg Age (Community) VCT Mod: Unknown Age, Female, Negative	
	Service Delivery Point by Agg Age (Community) VCT Mod: Unknown Age, Female, Positive	
	Service Delivery Point by Agg Age (Community) VCT Mod: Unknown Age, Male, Negative	
	Service Delivery Point by Agg Age (Community) VCT Mod: Unknown Age, Male, Positive	
GEND_GBV_DSD	Number of people receiving post-GBV care	155
	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	93
	By type of service: Sexual Violence (Post-Rape Care)	62
	By PEP service provision (related to sexual violence services provided)	
	<10, Female, Physical and/or Emotional Violence	
	<10, Female, Sexual Violence (Post-Rape Care)	
	<10, Male, Physical and/or Emotional Violence	
	<10, Male, Sexual Violence (Post-Rape Care)	
	10-14, Female, Physical and/or Emotional Violence	
	10-14, Female, Sexual Violence	

	(Post-Rape Care)	
	10-14, Male, Physical and/or Emotional Violence	
	10-14, Male, Sexual Violence (Post-Rape Care)	
	15-19, Female, Physical and/or Emotional Violence	
	15-19, Female, Sexual Violence (Post-Rape Care)	
	15-19, Male, Physical and/or Emotional Violence	
	15-19, Male, Sexual Violence (Post-Rape Care)	
	20-24, Female, Physical and/or Emotional Violence	
	20-24, Female, Sexual Violence (Post-Rape Care)	
	20-24, Male, Physical and/or Emotional Violence	
	20-24, Male, Sexual Violence (Post-Rape Care)	
	25-49, Female, Physical and/or Emotional Violence	
	25-49, Female, Sexual Violence (Post-Rape Care)	
	25-49, Male, Physical and/or Emotional Violence	
	25-49, Male, Sexual Violence (Post-Rape Care)	
	50+, Female, Physical and/or Emotional Violence	
	50+, Female, Sexual Violence (Post-Rape Care)	
	50+, Male, Physical and/or	

	Emotional Violence	
	50+, Male, Sexual Violence (Post-Rape Care)	
	Unknown Age, Female, Physical and/or Emotional Violence	
	Unknown Age, Female, Sexual Violence (Post-Rape Care)	
	Unknown Age, Male, Physical and/or Emotional Violence	
	Unknown Age, Male, Sexual Violence (Post-Rape Care)	
TB_ART_DSD	TB_ART_DSD Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	81 %
	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	58
	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	72
	Age/Sex: <1 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on	

	ART during TB treatment during the reporting period)	
	Age/Sex: Male 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 50+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-	

	positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 50+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	

	reporting period)	
	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	30
	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	28
	On ART: Already on ART	
	On ART: New on ART	
	Age/Sex: >1 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	

	Age/Sex: Male 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	

	Age/Sex: Female 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	37

	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	35
	TB_PREV_DSD TB_PREV_DSD	7 %
	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	1,167
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	15,640
	By Age/Sex (Denominator): <15, Female	
	By Age/Sex (Denominator): <15, Male	
	By Age/Sex (Denominator): 15+, Female	7,380

	By Age/Sex (Denominator): 15+, Male	7,379
	By Therapy type (Denominator): 6-12 Month IPT	15,640
	By Therapy type (Denominator): Alternative Regimen	
	By Therapy type (Denominator): Continuous IPT	
	By Age/Sex (Numerator): <15, Female	
	By Age/Sex (Numerator): <15, Male	
	By Age/Sex (Numerator): 15+, Female	539
	By Age/Sex (Numerator): 15+, Male	540
	By Therapy type (Numerator): 6-12 Month IPT	1,167
	By Therapy type (Numerator): Alternative Regimen	
	By Therapy type (Numerator): Continuous IPT	
TX_TB_DSD	TX_TB_DSD The proportion of ART patients who were screened who are receiving TB treatment	2 %
	Number of ART patients who were started on TB treatment during the reporting period.	281
	Number of ART patients who were screened for TB at least once during the reporting period	14,077
	Numerator: By Aggregated Age/Sex: <15, Female	
	Numerator: By Aggregated	

	Age/Sex: <15, Male	
	Numerator: By Aggregated Age/Sex: 15+, Female	141
	Numerator: By Aggregated Age/Sex: 15+, Male	140
	Denominator: By Aggregated Age/Sex: <15, Female	
	Denominator: By Aggregated Age/Sex: <15, Male	
	Denominator: By Aggregated Age/Sex: 15+, Female	43
	Denominator: By Aggregated Age/Sex: 15+, Male	43
	Denominator: By Screen Result: Negative	13,508
	Denominator: By Screen Result: Positive	268
	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	86
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	86
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	15,640
	Age/Sex: 15-19 Male	

	Age/Sex: 15-19 Female	
	Age/Sex: 20+ Female	
	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	
	Aggregated Age/Sex: 15+ Male	7,129
	Aggregated Age/Sex: <15 Female	
	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	8,510
	Sum of Aggregated Age/Sex <15	
	Sum of Aggregated Age/Sex 15+	15,639
	Sum of Aggregated Age/Sex disaggregates	15,639
	Age/Sex: <1	
	Age/Sex: <1-9	
	Age/Sex: 10-14 Male	
	Age/Sex: 10-14 Female	
	Aggregated Age/Sex: 1-14 Male	
	Age/Sex: 20-24 Male	
	Age/Sex: 25-49 Male	
	Age/Sex: 50+ Male	
	Age/Sex: 20-24 Female	
	Age/Sex: 25-49 Female	
	Age/Sex: 50+ Female	
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	3,533
	By Age/Sex: <1	
	By Age/Sex: 1-9	
	By Age/Sex: 10-14 Male	
	By Age/Sex: 15-19 Male	
	By Age/Sex: 20-24 Male	

	By Age/Sex: 25-49 Male	
	By Age/Sex: 50+ Male	
	By Age/Sex: 10-14 Female	
	By Age/Sex: 15-19 Female	
	By Age/Sex: 20-24 Female	
	By Age/Sex: 25-49 Female	
	By Age/Sex: 50+ Female	
	Aggregated Grouping by Age: <1	
	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex: <15 Male	
	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex: 15+ Male	1,619
	Aggregated Grouping by Age/Sex: <1 Female	
	Aggregated Grouping by Age/Sex: <15 Female	
	Aggregated Grouping by Age/Sex: 15+ Female	1,913
	Pregnancy status	
	Breastfeeding status	
	FSW	388
	MSM	620
	People in prisons and other enclosed settings	
	TG	
	Aggregated Grouping by Age/Sex: 1-14 Female	
	By Key populations: People who inject drugs (PWID)	

TX_PVLS_DSD	TX_PVLS_DSD Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	85 %
	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	12,438
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	14,632
	Numerator: Indication: Routine	12,438
	Numerator: Indication: Targeted	
	Numerator: Preg/BF by Indication: Pregnant Routine	
	Numerator: Preg/BF by Indication: Breastfeeding Routine	
	Numerator: Preg/BF by Indication: Pregnant Targeted	
	Numerator: Preg/BF by Indication: Breastfeeding Targeted	
	Numerator: Age/Sex by Indication: <1 Routine	
	Numerator: Age/Sex by Indication: 1-9 Routine	
	Numerator: Age/Sex by Indication: 10-14 Male Routine	
	Numerator: Age/Sex by Indication:	

	15-19 Male Routine	
	Numerator: Age/Sex by Indication: 20-24 Male Routine	
	Numerator: Age/Sex by Indication: 25-49 Male Routine	
	Numerator: Age/Sex by Indication: 50+ Male Routine	
	Numerator: Age/Sex by Indication: 10-14 Female Routine	
	Numerator: Age/Sex by Indication: 15-19 Female Routine	
	Numerator: Age/Sex by Indication: 20-24 Female Routine	
	Numerator: Age/Sex by Indication: 25-49 Female Routine	
	Numerator: Age/Sex by Indication: 50+ Female Routine	
	Numerator: Age/Sex by Indication: <1 Targeted	
	Numerator: Age/Sex by Indication: 1-9 Targeted	
	Numerator: Age/Sex by Indication: 10-14 Male Targeted	
	Numerator: Age/Sex by Indication: 15-19 Male Targeted	
	Numerator: Age/Sex by Indication: 20-24 Male Targeted	
	Numerator: Age/Sex by Indication: 25-49 Male Targeted	
	Numerator: Age/Sex by Indication: 50+ Male Targeted	
	Numerator: Age/Sex by Indication: 10-14 Female Targeted	
	Numerator: Age/Sex by Indication:	

	15-19 Female Targeted	
	Numerator: Age/Sex by Indication: 20-24 Female Targeted	
	Numerator: Age/Sex by Indication: 25-49 Female Targeted	
	Numerator: Age/Sex by Indication: 50+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	5,776
	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	6,660
	Denominator: Indication: Routine	9,774
	Denominator: Indication: Targeted	
	Denominator: Preg/BF by Indication: Pregnant Routine	
	Denominator: Preg/BF by Indication: Breastfeeding Routine	
	Denominator: Preg/BF by Indication: Pregnant Targeted	
	Denominator: Preg/BF by Indication: Breastfeeding Targeted	
	Denominator: Age/Sex by	

	Indication: <1 Routine	
	Denominator: Age/Sex by Indication: 1-9 Routine	
	Denominator: Age/Sex by Indication: 10-14 Male Routine	
	Denominator: Age/Sex by Indication: 15-19 Male Routine	
	Denominator: Age/Sex by Indication: 20-24 Male Routine	
	Denominator: Age/Sex by Indication: 25-49 Male Routine	
	Denominator: Age/Sex by Indication: 50+ Male Routine	
	Denominator: Age/Sex by Indication: 10-14 Female Routine	
	Denominator: Age/Sex by Indication: 15-19 Female Routine	
	Denominator: Age/Sex by Indication: 20-24 Female Routine	
	Denominator: Age/Sex by Indication: 25-49 Female Routine	
	Denominator: Age/Sex by Indication: 50+ Female Routine	
	Denominator: Age/Sex by Indication: <1 Targeted	
	Denominator: Age/Sex by Indication: 1-9 Targeted	
	Denominator: Age/Sex by Indication: 10-14 Male Targeted	
	Denominator: Age/Sex by Indication: 15-19 Male Targeted	
	Denominator: Age/Sex by Indication: 20-24 Male Targeted	
	Denominator: Age/Sex by	

	Indication: 25-49 Male Targeted	
	Denominator: Age/Sex by Indication: 50+ Male Targeted	
	Denominator: Age/Sex by Indication: 10-14 Female Targeted	
	Denominator: Age/Sex by Indication: 15-19 Female Targeted	
	Denominator: Age/Sex by Indication: 20-24 Female Targeted	
	Denominator: Age/Sex by Indication: 25-49 Female Targeted	
	Denominator: Age/Sex by Indication: 50+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	6,677
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	7,954
	Numerator Aggregated Age/Sex: <15 Male	
	Numerator Aggregated Age/Sex: 15+ Male	
	Numerator Aggregated Age/Sex:	

	<15 Female	
	Numerator Aggregated Age/Sex: 15+ Female	
	Denominator Aggregated Age/Sex: <15 Male	
	Denominator Aggregated Age/Sex: 15+ Male	
	Denominator Aggregated Age/Sex: <15 Female	
	Denominator Aggregated Age/Sex: 15+ Female	
	<15, Routine, Unknown Sex	
	<15, Targeted, Unknown Sex	
	<15, Undocumented Test Indication, Female	
	<15, Undocumented Test Indication, Male	
	<15, Undocumented Test Indication, Unknown Sex	
	15+, Routine, Unknown Sex	
	15+, Targeted, Unknown Sex	
	15+, Undocumented Test Indication, Female	
	15+, Undocumented Test Indication, Male	
	15+, Undocumented Test Indication, Unknown Sex	
	Unknown Age, Routine, Female	
	Unknown Age, Routine, Male	
	Unknown Age, Routine, Unknown Sex	
	Unknown Age, Targeted, Female	
	Unknown Age, Targeted, Male	

	Unknown Age, Targeted, Unknown Sex	
	Unknown Age, Undocumented Test Indication, Female	
	Unknown Age, Undocumented Test Indication, Male	
	Unknown Age, Undocumented Test Indication, Unknown Sex	
	Breastfeeding, Undocumented Test Indication	
	Pregnant, Undocumented Test Indication	
	Undocumented Test Indication	
	<15, Routine, Unknown Sex	
	<15, Targeted, Unknown Sex	
	<15, Undocumented Test Indication, Female	
	<15, Undocumented Test Indication, Male	
	<15, Undocumented Test Indication, Unknown Sex	
	15+, Routine, Unknown Sex	
	15+, Targeted, Unknown Sex	
	15+, Undocumented Test Indication, Female	
	15+, Undocumented Test Indication, Male	
	15+, Undocumented Test Indication, Unknown Sex	
	Unknown Age, Routine, Female	
	Unknown Age, Routine, Male	
	Unknown Age, Routine, Unknown Sex	
	Unknown Age, Targeted, Female	

	Unknown Age, Targeted, Male	
	Unknown Age, Targeted, Unknown Sex	
	Unknown Age, Undocumented Test Indication, Female	
	Unknown Age, Undocumented Test Indication, Male	
	Unknown Age, Undocumented Test Indication, Unknown Sex	
	Breastfeeding, Undocumented Test Indication	
	Pregnant, Undocumented Test Indication	
	Undocumented Test Indication	
TX_RET_DSD	TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	84 %
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	5,091
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	6,085
	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12	

	months after initiating ART	
	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	

	initiating ART	
	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the	

	beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	

	<p>Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
	<p>Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
	<p>Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
	<p>Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
	<p>Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)</p>	

	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Numerator by Status: Pregnant	
	Numerator by Status: Breastfeeding	
	Denominator by Status: Pregnant	
	Denominator by Status: Breastfeeding	
	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after	2,342

	initiating ART)	
	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,747
	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,799
	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age/Sex: 15+ Female	3,286

	<p>(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
--	---	--



Partners and Implementing Mechanisms

Partner List

Mech ID	Partner Name	Organization Type	Agency	Funding Source	Planned Funding
11972	IntraHealth International, Inc	NGO	U.S. Agency for International Development	GHP-USAID	550,000
14722	U.S. Department of Defense (Defense)	Other USG Agency	U.S. Department of Defense	GHP-State	0
17002	John Snow Inc (JSI)	Implementing Agency	U.S. Agency for International Development	GHP-State, GHP-USAID	1,775,000
17527	Ministry of Health (MOH)	Implementing Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	55,000
17561	Ministry of Health (MOH)	Implementing Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	163,941
17562	Centro de Orientacion e Investigacion Integral	NGO	U.S. Department of Health and Human Services/Centers for Disease	GHP-State	380,119

			Control and Prevention		
17608	Population Services International	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	588,957
17762	FHI 360	NGO	U.S. Agency for International Development	GHP-USAID	250,000
17915	Ministry of Health (MOH)	Implementing Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	224,001
18388	Clinical and Laboratory Standards Institute	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	100,000
18413	Abt Associates	Private Contractor	U.S. Agency for International Development		
18414	TBD	TBD	Redacted	Redacted	Redacted
18461	UNAIDS - Joint United Nations Programme on HIV/AIDS	Multi-lateral Agency	U.S. Agency for International Development	GHP-USAID	125,000
18462	Population	NGO	U.S. Agency for	GHP-USAID	53,000



	Services International		International Development		
18614	New Partner	TBD	U.S. Agency for International Development	GHP-USAID	150,000



Implementing Mechanism(s)

Implementing Mechanism Details

Mechanism ID: 11972	Mechanism Name: CAPACITY PLUS
Funding Agency: USAID	Procurement Type: USG Core
Prime Partner Name: IntraHealth International, Inc	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 550,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 200,000	
Total All Funding Sources and Applied Pipeline Amount: 750,000	
Funding Source	Funding Amount
GHP-USAID	550,000

Cross-Cutting Budget Attribution(s)

Human Resources for Health	463,000
Key Populations: MSM and TG	175,000

Budget Code Information

Mechanism ID: 11972			
Mechanism Name: CAPACITY PLUS			
Prime Partner Name: IntraHealth International, Inc			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	113,000	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	437,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14722	Mechanism Name: DOD
Funding Agency: DOD	Procurement Type: USG Core
Prime Partner Name: U.S. Department of Defense (Defense)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 104,600	
Total All Funding Sources and Applied Pipeline Amount: 104,600	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	14722
Mechanism Name:	DOD
Prime Partner Name:	U.S. Department of Defense (Defense)



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17002	Mechanism Name: ADVANCING PARTNERS AND COMMUNITIES (APC)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: John Snow Inc (JSI)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 1,775,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 1,425,000	
Total All Funding Sources and Applied Pipeline Amount: 3,200,000	
Funding Source	Funding Amount
GHP-State	656,068
GHP-USAID	1,118,932

Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	700,000
-----------------------------	---------



Key Populations: FSW	700,000
Gender: GBV	150,000

Budget Code Information

Mechanism ID: 17002			
Mechanism Name: ADVANCING PARTNERS AND COMMUNITIES (APC)			
Prime Partner Name: John Snow Inc (JSI)			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	415,409	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	313,729	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	269,409	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	776,453	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2018
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	12,887
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group	12,290



	level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	597
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	43,844
HTC_TST_DSD	By Test Result: Positive	2,157
HTC_TST_DSD	Sum of Test Result disaggregates	2,157
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Negative	16,413
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Positive	758
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Negative	13,082
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Positive	612
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Other: 15+, Female, Negative	1,501
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Other: 15+, Female, Positive	79
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Other: 15+, Male, Negative	9,517
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Other: 15+, Male, Positive	501
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Female, Negative	649
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Female, Positive	116
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Male, Negative	526



HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Male, Positive	93
HTC_TST_DSD	By Key Population: FSW, Negative	4,189
HTC_TST_DSD	By Key Population: FSW, Positive	219
HTC_TST_DSD	By Key Population: MSM, Negative	15,955
HTC_TST_DSD	By Key Population: MSM, Positive	865
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Negative	576
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Positive	30
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Negative	576
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Positive	30
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	120
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	151
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	60
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	60
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	75
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	76
GEND_GBV_DSD	Number of people receiving post-GBV care	90
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	54
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	36



TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	10,834
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	4,865
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	5,969
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	10,834
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	10,834
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	2,184
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	977
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	1,206
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	2,183
TX_NEW_DSD	FSW	266
TX_NEW_DSD	MSM	447
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	8,482
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	9,978
TX_PVLS_DSD	Numerator: Indication: Routine	8,482
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	3,909
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	4,572
TX_PVLS_DSD	Denominator: Indication: Routine	5,120
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	4,480
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	5,498
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	3,231
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting	3,866

	period, including those who have died, those who have stopped ART, and those lost to follow-up	
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,451
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,780
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,737
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,129
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	742
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	10,834
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	4,977
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	4,976
TB_PREV_DSD	By Therapy type (Denominator): 6-12 Month IPT	10,834
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	328
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	326
TB_PREV_DSD	By Therapy type (Numerator): 6-12 Month IPT	742



TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	195
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	9,751
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	98
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	97
TX_TB_DSD	Denominator: By Screen Result: Negative	9,569
TX_TB_DSD	Denominator: By Screen Result: Positive	182

Implementing Mechanism Details

Mechanism ID: 17527	Mechanism Name: (DIGECITSS) Improving PMTCT counseling, M&E of the PMTCT program, STI services and surveillance, establish performance management of HIV treatment, and capacity of the National Program to address strategic issues for Key Populations
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ministry of Health (MOH)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 55,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 125,000	
Total All Funding Sources and Applied Pipeline Amount: 180,000	
Funding Source	Funding Amount
GHP-State	55,000

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: Mechanism Name: Prime Partner Name:	17527 (DIGECITSS) Improving PMTCT counseling, M&E of the PMTCT program, STI services and surveillance, establish performance management of HIV treatment, and capacity of the National Program to address strategic issues for Key Populations Ministry of Health (MOH)		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	55,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17561	Mechanism Name: (MOH) Strengthening M&E, FETP capacity, health information systems (HIV, TB, laboratory data, and disease surveillance), Supply of safe blood, and national laboratory improvement plan in the DR MoH		
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement		
Prime Partner Name: Ministry of Health (MOH)			
Agreement Start Date: Redacted	Agreement End Date: Redacted		
TBD: No	New Mechanism: No		
Global Fund / Multilateral Engagement: N/A			
G2G: Yes	Managing Agency: HHS/CDC		

Total All Funding Sources: 163,941	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 489,000	
Total All Funding Sources and Applied Pipeline Amount: 652,941	
Funding Source	Funding Amount



GHP-State	163,941
-----------	---------

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 17561 Mechanism Name: (MOH) Strengthening M&E, FETP capacity, health information systems Prime Partner Name: (HIV, TB, laboratory data, and disease surveillance), Supply of safe blood, and national laboratory improvement plan in the DR MoH Ministry of Health (MOH)			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	163,941	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2018
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	58
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	72
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	30
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The	28



	number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	37
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	35

Implementing Mechanism Details

Mechanism ID: 17562	Mechanism Name: Increasing Self Sustainable and Friendly Clinical HIV/STI/TB Services for MSMs and Transgender Individuals in the Dominican Republic
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Centro de Orientacion e Investigacion Integral	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 380,119	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 675,000	
Total All Funding Sources and Applied Pipeline Amount: 1,055,119	
Funding Source	Funding Amount
GHP-State	380,119

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID:	17562		
Mechanism Name:	Increasing Self Sustainable and Friendly Clinical HIV/STI/TB Services for		
Prime Partner Name:	MSMs and Transgender Individuals in the Dominican Republic		
	Centro de Orientacion e Investigacion Integral		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	38,014	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	10,231	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	331,874	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	150
PrEP_NEW_DSD	Male 15-19	3
PrEP_NEW_DSD	Male 20-24	21
PrEP_NEW_DSD	Male 25-49	111
PrEP_NEW_DSD	Male 50+	15
PrEP_NEW_DSD	MSM	150
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	7,249
HTC_TST_DSD	By Test Result: Positive	527
HTC_TST_DSD	Sum of Test Result disaggregates	527



HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Female, Negative	808
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Female, Positive	90
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Male, Negative	911
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Male, Positive	101
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Negative	3,171
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Positive	223
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Negative	3,028
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Positive	212
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Female, Negative	278
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Female, Positive	49
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Male, Negative	244
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Male, Positive	43
HTC_TST_DSD	By Key Population: FSW, Negative	857
HTC_TST_DSD	By Key Population: FSW, Positive	75
HTC_TST_DSD	By Key Population: MSM, Negative	1,479
HTC_TST_DSD	By Key Population: MSM, Positive	111
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	21
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	26
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with	10

	documented HIV status, during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	11
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	13
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	13
GEND_GBV_DSD	Number of people receiving post-GBV care	65
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	39
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	26
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	4,139
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	1,932
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	2,207
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	4,139
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	4,139
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	973
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	455
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	518
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	973
TX_NEW_DSD	FSW	122
TX_NEW_DSD	MSM	173
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	3,311
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	3,895

TX_PVLS_DSD	Numerator: Indication: Routine	3,311
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	1,546
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	1,765
TX_PVLS_DSD	Denominator: Indication: Routine	3,895
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	1,819
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	2,076
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,532
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	1,833
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	729
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	803
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	870
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	963
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting	358

	period	
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	4,139
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	2,069
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	2,070
TB_PREV_DSD	By Therapy type (Denominator): 6-12 Month IPT	4,139
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	178
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	180
TB_PREV_DSD	By Therapy type (Numerator): 6-12 Month IPT	358
TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	74
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	3,725
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	37
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	37
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	37
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	37
TX_TB_DSD	Denominator: By Screen Result: Negative	3,651
TX_TB_DSD	Denominator: By Screen Result: Positive	74
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	74
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	74

Implementing Mechanism Details

Mechanism ID: 17608	Mechanism Name: Improving HIV/STI/TB Prevention, Treatment and Care Services for Mobile Populations in the Dominican Republic
----------------------------	--



Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Population Services International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 588,957	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 1,100,001	
Total All Funding Sources and Applied Pipeline Amount: 1,688,958	
Funding Source	Funding Amount
GHP-State	588,957

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17608		
Mechanism Name:	Improving HIV/STI/TB Prevention, Treatment and Care Services for		
Prime Partner Name:	Mobile Populations in the Dominican Republic		
	Population Services International		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	44,439	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	281,783	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	124,502	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	138,233	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	44,513
PP_PREV_DSD	Age/sex: 15-19 Male	3,491
PP_PREV_DSD	Age/sex: 20-24 Male	6,429
PP_PREV_DSD	Age/sex: 25-49 Male	12,546
PP_PREV_DSD	Age/sex: 50+ Male	1,726
PP_PREV_DSD	Age/sex: 15-19 Female	3,303
PP_PREV_DSD	Age/sex: 20-24 Female	6,104
PP_PREV_DSD	Age/sex: 25-49 Female	9,963
PP_PREV_DSD	Age/sex: 50+ Female	950
PP_PREV_DSD	Sum of Age/Sex disaggregates	44,512
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	39,023
HTC_TST_DSD	By Test Result: Positive	1,549
HTC_TST_DSD	Sum of Test Result disaggregates	1,549
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Female, Negative	8,743
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Female, Positive	270
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Male, Negative	20,401
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Male, Positive	631



HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Negative	2,511
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Positive	189
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Negative	2,511
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Positive	189
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Female, Negative	101
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Female, Positive	18
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Male, Negative	101
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Male, Positive	18
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: 15+, Female, Negative	1,301
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: 15+, Female, Positive	77
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: 15+, Male, Negative	1,804
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: 15+, Male, Positive	164
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	667
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	332
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	334
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	666
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	666
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	376
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	187
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	189



TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	376
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	645
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	759
TX_PVLS_DSD	Numerator: Indication: Routine	645
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	321
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	323
TX_PVLS_DSD	Denominator: Indication: Routine	759
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	378
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	380
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	328
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	386
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	162
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	164
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	192

TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	194
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	67
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	667
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	334
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	333
TB_PREV_DSD	By Therapy type (Denominator): 6-12 Month IPT	667
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	33
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	34
TB_PREV_DSD	By Therapy type (Numerator): 6-12 Month IPT	67
TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	12
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	601
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	6
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	6
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	6
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	6
TX_TB_DSD	Denominator: By Screen Result: Negative	288
TX_TB_DSD	Denominator: By Screen Result: Positive	12
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB	12



	disease	
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	12

Implementing Mechanism Details

Mechanism ID: 17762	Mechanism Name: LINKAGES
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 250,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 600,000	
Total All Funding Sources and Applied Pipeline Amount: 850,000	
Funding Source	Funding Amount
GHP-USAID	250,000

Cross-Cutting Budget Attribution(s)

Gender: GBV	250,000
-------------	---------

Budget Code Information

Mechanism ID: 17762			
Mechanism Name: LINKAGES			
Prime Partner Name: FHI 360			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	75,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	HVOP	75,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	100,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17915	Mechanism Name: Strengthening Strategic Information Capacity, Detection of HIV/TB Co-Infection and Clinical Services to Mobile Populations in the Dominican Republic		
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement		
Prime Partner Name: Ministry of Health (MOH)			
Agreement Start Date: Redacted	Agreement End Date: Redacted		
TBD: No	New Mechanism: No		
Global Fund / Multilateral Engagement: N/A			
G2G: Yes	Managing Agency: HHS/CDC		
Total All Funding Sources: 224,001		Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 750,003			
Total All Funding Sources and Applied Pipeline Amount: 974,004			
Funding Source	Funding Amount		
GHP-State	224,001		

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 17915		Mechanism Name: Strengthening Strategic Information Capacity, Detection of HIV/TB Co-Infection and Clinical Services to Mobile Populations in the Dominican Republic	
Prime Partner Name: Republic		Ministry of Health (MOH)	
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	28,018	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	44,827	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	151,156	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18388	Mechanism Name: GH13-1366, HQ, Strengthening and capacity building in resource constrained.
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Clinical and Laboratory Standards Institute	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 100,000	Total Mechanism Pipeline: N/A



Applied Pipeline Amount: 400,000	
Total All Funding Sources and Applied Pipeline Amount: 500,000	
Funding Source	Funding Amount
GHP-State	100,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	18388		
Mechanism Name:	GH13-1366, HQ, Strengthening and capacity building in resource constrained.		
Prime Partner Name:	Clinical and Laboratory Standards Institute		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	100,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18413	Mechanism Name: Health Finance and Governance (HFG)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Abt Associates	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	



G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

(No data provided.)

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18414	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18461	Mechanism Name: UNAIDS III
Funding Agency: USAID	Procurement Type: Grant
Prime Partner Name: UNAIDS - Joint United Nations Programme on HIV/AIDS	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:



Total All Funding Sources: 125,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 75,000	
Total All Funding Sources and Applied Pipeline Amount: 200,000	
Funding Source	Funding Amount
GHP-USAID	125,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	18461		
Mechanism Name:	UNAIDS III		
Prime Partner Name:	UNAIDS - Joint United Nations Programme on HIV/AIDS		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	125,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18462	Mechanism Name: SIFPO2
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Population Services International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	



G2G: No	Managing Agency:
---------	------------------

Total All Funding Sources: 53,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 100,000	
Total All Funding Sources and Applied Pipeline Amount: 153,000	
Funding Source	Funding Amount
GHP-USAID	53,000

Cross-Cutting Budget Attribution(s)

Condom programming	53,000
--------------------	--------

Budget Code Information

Mechanism ID: 18462			
Mechanism Name: SIFPO2			
Prime Partner Name: Population Services International			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	53,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18614	Mechanism Name: Building Indigenous NGOs Sustainability (BINGOS)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: New Partner	
Agreement Start Date: Redacted	Agreement End Date: Redacted



TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 150,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 150,000	
Funding Source	Funding Amount
GHP-USAID	150,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 18614			
Mechanism Name: Building Indigenous NGOs Sustainability (BINGOS)			
Prime Partner Name: New Partner			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	150,000	0

Implementing Mechanism Indicator Information

(No data provided.)



**Agency Information - Costs of Doing Business
U.S. Agency for International Development**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
ICASS			194,325	194,325	64,103	258,428
Non-ICASS Administrative Costs			100,689	100,689	104,874	205,563
Staff Program Travel			123,981	123,981	42,129	166,110
USG Staff Salaries and Benefits - Internationally Recruited		100,000	55,295	155,295	193,574	348,869
USG Staff Salaries and Benefits - Locally Recruited		100,000	62,710	162,710	195,320	358,030
Total	0	200,000	537,000	737,000	600,000	1,337,000

U.S. Department of Defense

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and
-------------------------------	-----	-----------	-----------	----------------------	------------------	-------------------------------



						Applied Pipeline Amount
Computers/IT Services		0		0	3,800	3,800
ICASS		0		0	8,000	8,000
Indirect Costs		0		0	1,000	1,000
Staff Program Travel		0		0	16,762	16,762
USG Staff Salaries and Benefits - Locally Recruited				0	76,838	76,838
Total	0	0	0	0	106,400	106,400

U.S. Department of Health and Human Services/Centers for Disease Control and Prevention

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Capital Security Cost Sharing		70,000		70,000	0	70,000
Computers/IT Services		30,000		30,000	0	30,000
ICASS		230,000		230,000	0	230,000
Institutional Contractors		388,000		388,000	0	388,000
Non-ICASS Administrative		401,983		401,983	0	401,983



Costs						
Staff Program Travel		110,000		110,000	0	110,000
USG Staff Salaries and Benefits - Internationally Recruited	387,500	101,499		488,999	124,996	613,995
USG Staff Salaries and Benefits - Locally Recruited	0	594,000		594,000	0	594,000
Total	387,500	1,925,482	0	2,312,982	124,996	2,437,978